SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Akums Drugs and Pharmaceuticals informs about annual report

19 Jun 2026 Evaluate
Akums Drugs and Pharmaceuticals has informed that Akums Drugs and Pharmaceuticals (the Company) has sent a letter providing the web-link, including the exact path, where the Integrated Annual Report of the Company for the Financial Year 2025-26 is available, to those members who have not registered their e-mail ID’s with the Company/ MUFG Intime India (formerly known as Link Intime India) - Registrar and Transfer Agent Depositories (RTA)/ Depository Participants (DPs). A copy of the letter is enclosed as ‘Annexure - A’.

The above information is a part of company’s filings submitted to BSE.

Akums Drugs & Pharma Share Price

620.75 3.20 (0.52%)
23-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1867.80
Dr. Reddys Labs. 1301.30
Cipla 1433.10
Zydus Lifesciences 1112.10
Lupin 2356.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: